JP2019509253A5 - - Google Patents

Download PDF

Info

Publication number
JP2019509253A5
JP2019509253A5 JP2018532746A JP2018532746A JP2019509253A5 JP 2019509253 A5 JP2019509253 A5 JP 2019509253A5 JP 2018532746 A JP2018532746 A JP 2018532746A JP 2018532746 A JP2018532746 A JP 2018532746A JP 2019509253 A5 JP2019509253 A5 JP 2019509253A5
Authority
JP
Japan
Prior art keywords
phosphate
alaninyl
benzoxy
gemcitabine
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018532746A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019509253A (ja
JP6898329B2 (ja
Filing date
Publication date
Priority claimed from PCT/GB2015/054158 external-priority patent/WO2017109444A1/en
Priority claimed from GBGB1609770.1A external-priority patent/GB201609770D0/en
Application filed filed Critical
Priority claimed from PCT/GB2016/054018 external-priority patent/WO2017109486A1/en
Publication of JP2019509253A publication Critical patent/JP2019509253A/ja
Publication of JP2019509253A5 publication Critical patent/JP2019509253A5/ja
Application granted granted Critical
Publication of JP6898329B2 publication Critical patent/JP6898329B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018532746A 2015-12-23 2016-12-21 併用療法 Expired - Fee Related JP6898329B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/GB2015/054158 WO2017109444A1 (en) 2015-12-23 2015-12-23 Combination therapy
GBPCT/GB2015/054158 2015-12-23
GBGB1609770.1A GB201609770D0 (en) 2016-06-03 2016-06-03 Combination therapy
GB1609770.1 2016-06-03
PCT/GB2016/054018 WO2017109486A1 (en) 2015-12-23 2016-12-21 Combination therapy

Publications (3)

Publication Number Publication Date
JP2019509253A JP2019509253A (ja) 2019-04-04
JP2019509253A5 true JP2019509253A5 (enExample) 2020-01-09
JP6898329B2 JP6898329B2 (ja) 2021-07-07

Family

ID=57681677

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018532746A Expired - Fee Related JP6898329B2 (ja) 2015-12-23 2016-12-21 併用療法

Country Status (29)

Country Link
US (2) US20190022117A1 (enExample)
EP (2) EP3738595A1 (enExample)
JP (1) JP6898329B2 (enExample)
KR (1) KR20180096698A (enExample)
CN (1) CN108697725A (enExample)
AU (1) AU2016375861B2 (enExample)
CA (1) CA3008749C (enExample)
CY (1) CY1122835T1 (enExample)
DK (1) DK3393478T3 (enExample)
EA (1) EA037459B1 (enExample)
ES (1) ES2778933T3 (enExample)
HR (1) HRP20200423T1 (enExample)
HU (1) HUE050290T2 (enExample)
IL (1) IL260076A (enExample)
LT (1) LT3393478T (enExample)
MA (1) MA51576A (enExample)
MD (1) MD3393478T2 (enExample)
ME (1) ME03677B (enExample)
MX (1) MX383988B (enExample)
MY (1) MY194629A (enExample)
PH (1) PH12018501339A1 (enExample)
PL (1) PL3393478T3 (enExample)
PT (1) PT3393478T (enExample)
RS (1) RS60211B1 (enExample)
SG (1) SG11201805184TA (enExample)
SI (1) SI3393478T1 (enExample)
SM (1) SMT202000154T1 (enExample)
WO (1) WO2017109486A1 (enExample)
ZA (1) ZA201804155B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013346515B2 (en) 2012-11-16 2017-05-25 NuCana plc Process for preparing nucleoside prodrugs
EA033046B1 (ru) 2014-06-25 2019-08-30 НУКАНА ПиЭлСи Состав, содержащий пролекарство гемцитабина
RS60968B1 (sr) 2014-06-25 2020-11-30 NuCana plc Prolekovi gemcitabina
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
PH12018500691B1 (en) 2015-10-05 2022-08-10 NuCana plc Combination therapy
CA3007347C (en) 2015-12-11 2020-08-04 NuCana plc Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
EA201491629A1 (ru) * 2012-08-13 2015-08-31 Регулон, Инк. Способы лечения рака с использованием липоплатина
JP6420247B2 (ja) * 2012-11-13 2018-11-07 ボーイエン セラピューティクス,インコーポレイティド ゲムシタビンプロドラッグ及びその使用
CN107835687A (zh) * 2015-05-14 2018-03-23 努卡那有限公司 癌症治疗
PH12018500691B1 (en) * 2015-10-05 2022-08-10 NuCana plc Combination therapy

Similar Documents

Publication Publication Date Title
Monneret Platinum anticancer drugs. From serendipity to rational design
US20180256578A1 (en) A Combination Therapy Comprising Varlitinib and an Anticancer Agent
Chae et al. Statins as anti-cancer therapy; Can we translate preclinical and epidemiologic data into clinical benefit?
JP2019532051A5 (enExample)
JP2020535173A5 (enExample)
BR112013011480B1 (pt) Uso de pm01183 ou um sal farmaceuticamente aceitável do mesmo e kit para uso no tratamento de câncer
JP2012521435A5 (enExample)
JP2023533464A5 (enExample)
HRP20200423T1 (hr) Kombinirana terapija
JP2012506448A5 (enExample)
JP7193591B2 (ja) 化学療法の改善
JP2014533277A5 (enExample)
JP2020523356A5 (enExample)
BR112021007283A2 (pt) método de tratamento de um câncer ou câncer refratário
CN102056609B (zh) 药物组合
JP2021505669A5 (enExample)
ES2389809T3 (es) Terapias anticancerosas
JP2021528480A5 (enExample)
Hu et al. Current status of CPT and its analogues in the treatment of malignancies
WO2021048417A1 (en) Combination therapies comprising dasatinib for the treatment of cholangiocarcinoma
BR112019019491A2 (pt) sulfoximina butionina e um metalofármaco para tratamento de câncer, hiv ou uma doença reumática
JP2024520307A5 (enExample)
JP6458007B2 (ja) 抗腫瘍性白金錯体を含有する抗腫瘍剤及び抗腫瘍効果増強剤
AU2020346384B2 (en) Combination therapies comprising panobinostat for the treatment of cholangiocarcinoma
Lamarca et al. Biliary tract tumors: past, present and future